Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Net Income (2016 - 2025)

Celldex Therapeutics has reported Net Income over the past 16 years, most recently at -$81.3 million for Q4 2025.

  • Quarterly results put Net Income at -$81.3 million for Q4 2025, down 72.68% from a year ago — trailing twelve months through Dec 2025 was -$258.8 million (down 63.91% YoY), and the annual figure for FY2025 was -$258.8 million, down 63.91%.
  • Net Income for Q4 2025 was -$81.3 million at Celldex Therapeutics, down from -$67.0 million in the prior quarter.
  • Over the last five years, Net Income for CLDX hit a ceiling of -$13.4 million in Q2 2021 and a floor of -$81.3 million in Q4 2025.
  • Median Net Income over the past 5 years was -$34.3 million (2024), compared with a mean of -$37.0 million.
  • Biggest five-year swings in Net Income: crashed 169.23% in 2022 and later grew 15.28% in 2023.
  • Celldex Therapeutics' Net Income stood at -$20.2 million in 2021, then plummeted by 31.29% to -$26.5 million in 2022, then tumbled by 63.5% to -$43.3 million in 2023, then fell by 8.74% to -$47.1 million in 2024, then plummeted by 72.68% to -$81.3 million in 2025.
  • The last three reported values for Net Income were -$81.3 million (Q4 2025), -$67.0 million (Q3 2025), and -$56.6 million (Q2 2025) per Business Quant data.